DRUG |
MANUFACTURER |
|
Abatacept (Orencia, CTLA-4-Ig) for autoimmune diseases |
Bristol-Myers Squibb (App'd for severe R.A. by FDA) |
| RG2077 (CTLA4-Ig)
(2005) |
Repligen
(Phase I for MS and Lupus) |
|
Arcalyst (rilonacept, anti-IL-1) for selected AI diseases |
Regeneron Pharmaceuticals (Fast tracked |
|
Anti-TNF (anti-Tumor
Necrosis Factor) Drugs: CENTO
148 (Human anti-TNF Mab)
Cimzia (certolizumab pegol,
pegylated-antiTNF alpha) Simponi (Golimumab) |
ISIS Laboratories (Ph. II for R.A.) AMGEN Centocor (Ph I for R.A.) Briston-Myers Squibb (Ph. II for R.A.)
Applied
Molecular Evolution, Inc. (Ph I/II for R.A.) UCB Nektar (FDA approved for Crohn's disease & R.A.) Centocor Ortho Biotech Inc. (FDA approved for arthritic conditions) |
|
ABT874 (Human anti-IL 12) |
Abbot Laboratories (Phase II for R.A./Crohn's) |
|
CAT192 (Human anti-TGF? monoclonal AB) |
Cellcept (For systemic sclerosis) |
| Epratumzamab (Anti-CD-22) |
Immunomedics
(Unpecified autoimmune diseases) |
|
Kineret (Anakinra,
Anti-IL-1ra monoclonal |
Amgen (Approved for R.A.) |
| HuMax ( Ofatumumab, Human
anti-IL-15
Mab) |
Genmab/Amgen/Medarex (Phase II for R.A.) |
| Ipilimumab (MDX-010-fully
human antibody that blocks CTLA-4) |
Bristol-Myers
Squibb (Phase
I/II for prostate cancer, melanoma) |
| Pralnacasan (Small
molecule
interleukine-1 converting enzyme [ICE] inhibitor) |
Vertex
(Phase II for RA) |
| VX-740
(Small molecule interleuking-1 converting enzyme [ICE] inhibitor) |
Aventis
(Phase II for R.A.) |
| IL-1 Trap
(IL-1 receptor fusion protein |
Regeneron
(Phase
II for R.A.) |
| sIL-1r2
(Soluble IL-1 receptor type II)
|
Amgen
(Phase I for R.A.) |
| MRA (Humanized
anti-IL-6 receptor Mab) |
Chugai
(Phase II for R.A.) |
|
CD4 antibody |
TolerRxInc |
|
CD18 antibody (LDP-01) |
LeukoSite, Inc. (affects white cell adhesion) |
|
Aglycosyl CD3 antibody (modified OKT-3) |
Therapeutic Antibody Center |
| HuMax-CD20
(Targets B cells)
|
Gemmab (Preclinical development for various autoimmune diseases) |
| AME-133 (Anti-CD 20, B cell suppressant) |
Applied Molecular Evolution, Inc. (Preclinical) |
|
Raptiva (Efalizumab,
anti-CD11a) WITHDRAWEN by FDA |
Genentech
and XOMA (Ph.
III for Psoriasis, not R.A.) |
|
Amevive (Alefacept,
targets
|
Biogen (Chronic Plaque Psoriasis) |
|
Antegren (Natalizumab
Alpha-4 WITHDRAWN |
Elan Corporation, plc and
Biogen, Inc. (Ph II for |
| SCIO-469 (Inhibits
p38 kinase TNF-alpha, IL-1, SCIO-323 and (COX-2) |
SCIOS (May be acquired by Johnson & Johnson; SCIO-323 is 2nd Generation) |
| VX-702 (p38 MAP kinase inhibitor |
VERTEX
(Phase
II for R.A.) |
| 681323
(p38 MAP kinase inhibitor)
|
GlaxoSmithKline
(Phase
I for R.A.) |
| BIRB796 (p38
MAP kinase inhibitor) |
Boehringer Ingelheim (Phase
II for R.A.) |
| LymphoStat-B
(Belimumab;anti-BLyS,
one of the BAFFs, fully-human IgG1-λ monoclonal antibody) |
Human Genome Sciences (Phase II for SLE) |
| TACI-Ig (Inhibits BLyS & APRIL) |
ZymoGenetics and Serono (Phase I in
U.K.) |
| Eculizumab (Inhibits C5 complement) | Alexion
Pharmaceuticals, Inc. (Phase III for RA) |
| Bexxar (Anti-CD20) | GlaxoSmithKline
(Approved for NH
lymphoma) |
| BG9588 (Anti-CD40L) |
BioGen
(SLE, possibly other AI) |
|
TKB662 (Inhibits activation
and
proliferation of T & B cells) |
Isotecknika,
Inc.
(Experimental, psoriasis steroid sparing) |
|
ISA247 (Calcineurin
inhibitor)
|
Isotecknika,
Inc.
(Phase III for psoriasis) |
|
CP-690,550 (Inhibits enzyme JAK3 in immune cells) |
Pfizer
(Not ready for human use) |
| PLX647 (dual c-Kit and FMS kinase inhibitor) | Plexxikon
(Pre-clinical
for psoriasis) |
| Riquent®
(Abetimus
sodium)
|
La
Jolla Pharmaceutical Co. (Phase III for lupus) |
| AK216348 (Selective glucocorticoid receptor agonists (SEGRA) |
Experimental |
| NCX-1015 (Nitrosteroid,appears to not active osteoclasts) |
Experimental |
| IMATINIB (Anti-IL-5, Gleevec
(USA) or Glivec (Europe/Australia) |
Novartis Pharmaceuticals
(FDA approved for chronic myelogenous leukemia) |
| Mepolizumab (Anti-IL-5 for
hypereosinophilia, trade name- Bosatria |
SmithKlineBeecham
U.K. (Phase i for Hypereosinophilic
Syndromes) (Phase II for Eosinophilic Gastroenteritis, Churg-Strauss Syndrome, Eosinophilic Esophagitis |
| Omalizumab (Xolair is a monoclonal anti-IL-5 antibody) |
Genentech /
Novartis (Approved for chronic asthma in
adults. Can cause anaphylaxis in a small percentage of patients) |
|
Reslizumab (Humanized anti-IL-5 monoclonal antibody) |
Ception Therapeutics Inc (Intended for the treatment of
eosinophil- <> meditated inflammations of
the airways,skin
and
gastrointestinal tract.
As of September 2009,
it isundergoing Phase II/III
clinical trials
|
|
HuMax (Ofatumumab, Anti-CD20) |
Genmab (GlaxoSmithKline)
(Phase III
for RA and NHL) |
| TRU-015 (Anti-CD20) | Trubion
Pharmaceuticals (Phase I
for RA) |
| Ocrelizumab (humanized anti CD20) | Genentech
(Phase III for RA, SLE, lupus
nephritis
phase
II for relapsing
MS)
|
| Tocilizumab
[Actemra] (humanized
anti IL-6 receptor antibody) |
Roche and
Chugai
Possibly known as atlizumab |
| Veltuzumab (humanized anti-CD20 for sub-cutaneous injection) |
Immunomedics-Nycomed In development for autoimmune
diseases Ph 1/2 for ITP to start |
| SGN-70 (anti-CD70) | Seattle
Genetics
(Phase I for
autoimmune lymphocytic diseases) |
| AQX-MN100 (Inhibitits immune cell activation) |
Aquinox Pharmaceuticals (Early
development) |
| Atacicept (Anti BlyS/CD257and APRIL/CD256, B cell suppressant) |
Merck KGaA.
(formerly
ZynoGenetics) (Phase
1 completed) |
# It is known by several
other names including HAT (Humanized Anti-Tac), SMART anti-Tac,
and humanized
anti-IL2-receptor.
See also http://www.bitsplace.com/bitsplace/Autoimmunediscomp.html
The following table is from a September 2007 article at http://en.wikipedia.org/wiki/Certolizumab_pegol